JP Morgan Chase
NBSE

JP Morgan Chase’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

JP Morgan Chase’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-539
Closed -$997 – 7796
2023
Q2 		$997 Buy
+539
New +$1.78K ﹤0.01% 6457
2022
Q4 		– Sell
-1
Closed – – 7136
2022
Q3 		$0 Buy
+1
New +$17 ﹤0.01% 6973
2021
Q4 		– Sell
-19
Closed -$1K – 7053
2021
Q3 		$1K Sell
19
-2,397
-99% -$183K ﹤0.01% 6417
2021
Q2 		$231K Sell
2,416
-145
-6% -$16K ﹤0.01% 5163
2021
Q1 		$379K Buy
2,561
+132
+5% +$23.9K ﹤0.01% 4843
2020
Q4 		$340K Buy
2,429
+1,913
+371% +$310K ﹤0.01% 4582
2020
Q3 		$78K Sell
516
-129
-20% -$21K ﹤0.01% 4812
2020
Q2 		$113K Buy
+645
New +$108K ﹤0.01% 4520
2020
Q1 		– Sell
-687
Closed -$99K – 5815
2019
Q4 		$99K Buy
+687
New +$80.6K ﹤0.01% 4905
2018
Q3 		– Sell
-7
Closed -$1K – 5879
2018
Q2 		$1K Hold
7
– – ﹤0.01% 5501
2018
Q1 		$1K Sell
7
-48
-87% -$7.14K ﹤0.01% 5328
2017
Q4 		$41K Buy
+55
New +$21.2K ﹤0.01% 4955

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase's NBSE Position: Q3 2023 in Review

JP Morgan Chase sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2023, closing a stake of 539 shares — an estimated $997 sold.

JP Morgan Chase first reported a position in NBSE in Q4 2017 and held it in 12 quarters. The position peaked at $379K in Q1 2021. 21 funds tracked by Wall St. Rank hold NBSE as of Q3 2023.

  • JP Morgan Chase reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 539 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $997.
  • JP Morgan Chase first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2017 and held it in 12 quarters.
  • JP Morgan Chase's NeuBase Therapeutics, Inc. Common Stock position peaked at $379K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.